.

BioPharmaceutical Business Intelligence

  • Analyze global market entry opportunities
  • Uncover prior art in expired and abandoned patents
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Federal Trade Commission
AstraZeneca
Accenture
Daiichi Sankyo
Cantor Fitzgerald
McKinsey
US Department of Justice
Cipla
Novartis
Argus Health

Generated: December 15, 2017

DrugPatentWatch Database Preview

Janssen R And D Company Profile

« Back to Dashboard

What is the competitive landscape for JANSSEN R AND D, and when can generic versions of JANSSEN R AND D drugs launch?

JANSSEN R AND D has two approved drugs.

There are four US patents protecting JANSSEN R AND D drugs.

There are one hundred and thirty-four patent family members on JANSSEN R AND D drugs in thirty-nine countries and twelve supplementary protection certificates in eleven countries.

Summary for Janssen R And D

International Patents:134
US Patents:4
Tradenames:2
Ingredients:2
NDAs:2
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Patent Submitted Product Substance Delist Req. Exclusivity Expiration
Janssen R And DINTELENCEetravirineTABLET;ORAL022187-002Dec 22, 2010RXYesYes► Subscribe► Subscribe► SubscribeYY► Subscribe
Janssen R And DINTELENCEetravirineTABLET;ORAL022187-001Jan 18, 2008RXYesNo► Subscribe► Subscribe► SubscribeYY► Subscribe
Janssen R And DINTELENCEetravirineTABLET;ORAL022187-003Mar 26, 2012RXYesNo► Subscribe► Subscribe► SubscribeY► Subscribe
Janssen R And DPARAFON FORTE DSCchlorzoxazoneTABLET;ORAL011529-002Jun 15, 1987DISCNYesNo► Subscribe► Subscribe► Subscribe► Subscribe
Janssen R And DINTELENCEetravirineTABLET;ORAL022187-002Dec 22, 2010RXYesYes► Subscribe► Subscribe► SubscribeY► Subscribe
Janssen R And DINTELENCEetravirineTABLET;ORAL022187-002Dec 22, 2010RXYesYes► Subscribe► Subscribe► SubscribeYY► Subscribe
Janssen R And DINTELENCEetravirineTABLET;ORAL022187-001Jan 18, 2008RXYesNo► Subscribe► Subscribe► SubscribeY► Subscribe
Janssen R And DINTELENCEetravirineTABLET;ORAL022187-003Mar 26, 2012RXYesNo► Subscribe► Subscribe► SubscribeYY► Subscribe
Janssen R And DINTELENCEetravirineTABLET;ORAL022187-001Jan 18, 2008RXYesNo► Subscribe► Subscribe► SubscribeYY► Subscribe
Janssen R And DINTELENCEetravirineTABLET;ORAL022187-001Jan 18, 2008RXYesNo► Subscribe► Subscribe► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Janssen R And D

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,530,655HIV replication inhibiting pyrimidines► Subscribe
7,015,2212,4-disubstituted triazine derivatives► Subscribe
7,241,458Antiviral compositions► Subscribe
6,638,932 2,4-disubstituted triazine derivatives► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Janssen R And D Drugs

Country Document Number Estimated Expiration
Poland347586► Subscribe
New Zealand511116► Subscribe
Bulgaria106521► Subscribe
South Africa200103768► Subscribe
Canada2350801► Subscribe
Norway2009003► Subscribe
Spain2258018► Subscribe
Norway319788► Subscribe
China1214013► Subscribe
World Intellectual Property Organization (WIPO)0027825► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Janssen R And D Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
2009000003Germany► SubscribePRODUCT NAME: ETRAVIRIN UND DESSEN ADDITIONSSALZE; REGISTRATION NO/DATE: EU/1/08/468/001 20080828
C/GB09/003United Kingdom► SubscribeSUPPLEMENTARY PROTECTION CERTIFICATE NO SPC/GB09/003 GRANTED TO JANSSEN PHARMACEUTICA NV IN RESPECT OF THE PRODUCT ETRAVIRINE OPTIONALLY IN A FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT, THE GRANT OF WHICH WAS ADVERTISED IN JOURNAL NO 6342 DATED 08 DECEMBER 2010 HAS HAD ITS MAXIMUM PERIOD OF DURATION CORRECTED, SUBJECT TO THE PAYMENT OF THE PRESCRIBED FEES IT WILL EXPIRE ON 31 AUGUST 2023.
2008016Lithuania► SubscribePRODUCT NAME: ETRAVIRINUM; REG. NO/DATE: EU/1/08/468/001 20080828
7Finland► Subscribe
C0004France► SubscribePRODUCT NAME: ETRAVIRINE AINSI QUE SES SELS PHARMACEUTIQUEMENT ACCEPTABLES; REGISTRATION NO/DATE IN FRANCE: EU/1/08/468/001 DU 20080828; REGISTRATION NO/DATE AT EEC: EU/1/08/468/001 DU 20080828
0373Netherlands► Subscribe300373, 20191101, EXPIRES: 20230827
2008016,C1002795Lithuania► SubscribePRODUCT NAME: ETRAVIRINUM; REGISTRATION NO/DATE: EU/1/08/468/001 20080828
C033/2008Ireland► SubscribeSPC033/2008: 20090914, EXPIRES: 20230827
1002795/01Switzerland► SubscribePRODUCT NAME: ETRAVIRIN; REGISTRATION NUMBER/DATE: SWISSMEDIC 58483 13.05.2008
5/2009Austria► SubscribePRODUCT NAME: ETRAVIRIN UND DESSEN ADDITIONSSALZE
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Similar Applicant Names

Individual applicants are sometimes listed under multiple names.
Here is a list of applicants with similar names.

« Back to Dashboard

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Medtronic
Accenture
Cipla
UBS
Queensland Health
US Army
Express Scripts
Deloitte
Dow
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot